Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 6, 2013, Pages 558-564

  Renouf, Daniel J ^a   Woods, Ryan ^a   Speers, Caroline ^a   Hay, John ^a   Phang, P Terry ^a   Fitzgerald, Catherine ^a   Kennecke, Hagen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Colon cancer; Outcomes; Radiation therapy; Rectal cancer; Surgery; Total mesorectal excision

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COLON CANCER; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MONOTHERAPY; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; RECTUM CANCER; SURVIVAL;

AGED; BRITISH COLUMBIA; CHEMORADIOTHERAPY; COHORT STUDIES; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE PERIOD; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84892614322     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318256f5dc     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Cancer Research UK Cancer Statistics. Available at: http:// cancerresearchuk.org/cancerstats/incidence/index.htm. Accessed October 22, 2010.
3. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644-5650.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-1425.
5. Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004;22:1778-1784.
6. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
7. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23: 4866-4875.
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
9. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
10. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
11. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
13. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357: 2040-2048.
14. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980-987.
15. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol. 2005;23: 5620-5627.
16. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123.
17. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
18. Arbman G, Nilsson E, Hallbook O, et al. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg. 1996;83:375-379.
19. Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335-346.
20. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457-460.
21. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693-701.
22. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
23. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009; 27:5124-5130.
24. Cheifetz RE, Phang PT. Evaluating learning and knowledge retention after a continuing medical education course on total mesorectal excision for surgeons. Am J Surg. 2006;191:687-690.
25. Canadian Cancer Society: Canadian Cancer Statistics, 2010.
26. Renouf D, Kennecke H, Gill S. Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 2008;7: 386-389.
27. Gunderson LL, Jessup JM, Sargent DJ, et al. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28:256-263.
28. Elferink MA, van Steenbergen LN, Krijnen P, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer. 2010;46:1421-1429.
29. Birgisson H, Talback M, Gunnarsson U, et al. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31:845-853.
30. Dahlberg M, Pahlman L, Bergstrom R, et al. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 1998;85:515-520.
31. Quasar Collaborative G, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-2029.
32. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
33. Hofheinz R, Wenz F, Post S, et al. Capecitabine versus 5-fluorouracil based (neo) adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized, phase III trial. J Clin Oncol. 2009;27:15s. (suppl; abstr 4014).
34. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto-01 randomized phase III trial. J Clin Oncol. 2009;27:18s (suppl; abstr CRA4008).
35. Gerard J, Azria D, Gourgon-Bourgade S, et al. Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy regimens (RT45-Cap versus RT50-Capox) in patients with locally advanced rectal cancer. J Clin Oncol. 2009;27:18s (Suppl; abstr LBA 4007).